List of Ligand Pharmaceuticals patents

Patents where

Current Assignee

Name

Ligand Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10449210 Prodrug compounds and their uses	Patent 10449210 was granted and assigned to Ligand Pharmaceuticals on October, 2019 by the United States Patent and Trademark Office.	Ligand Pharmaceuticals	Ligand Pharmaceuticals	United States Patent and Trademark Office	10449210	October 22, 2019
‌ US Patent 10030034 Heterocycle amines and uses thereof	Patent 10030034 was granted and assigned to Ligand Pharmaceuticals on July, 2018 by the United States Patent and Trademark Office.	Ligand Pharmaceuticals	Ligand Pharmaceuticals	United States Patent and Trademark Office	10030034	July 24, 2018
‌ US Patent 7214690 Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods	Patent 7214690 was granted and assigned to Ligand Pharmaceuticals on May, 2007 by the United States Patent and Trademark Office.		Ligand Pharmaceuticals	United States Patent and Trademark Office	7214690	May 8, 2007
‌ US Patent 7098310 Heterodimers of retinoid X receptors (RXRS) and other steroid hormone receptors	Patent 7098310 was granted and assigned to Ligand Pharmaceuticals on August, 2006 by the United States Patent and Trademark Office.		Ligand Pharmaceuticals	United States Patent and Trademark Office	7098310	August 29, 2006
‌ US Patent 7098025 Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor	Patent 7098025 was granted and assigned to Ligand Pharmaceuticals on August, 2006 by the United States Patent and Trademark Office.		Ligand Pharmaceuticals	United States Patent and Trademark Office	7098025	August 29, 2006
‌ US Patent 11186593 Heterocycle amines and uses thereof	Patent 11186593 was granted and assigned to Ligand Pharmaceuticals on November, 2021 by the United States Patent and Trademark Office.	Ligand Pharmaceuticals	Ligand Pharmaceuticals	United States Patent and Trademark Office	11186593	November 30, 2021
‌ US Patent 11413274 Methods and compositions associated with the granulocyte colony-stimulating factor receptor		Ligand Pharmaceuticals	Ligand Pharmaceuticals	United States Patent and Trademark Office	11413274	August 16, 2022
‌ US Patent 9326991 Nucleotide prodrug compounds and use	Patent 9326991 was granted and assigned to Ligand Pharmaceuticals on May, 2016 by the United States Patent and Trademark Office.		Ligand Pharmaceuticals	United States Patent and Trademark Office	9326991	May 3, 2016
‌ US Patent 7435733 Mineralocorticoid receptor modulator compounds and methods, and pharmaceutical compositions containing these compounds	Patent 7435733 was granted and assigned to Ligand Pharmaceuticals on October, 2008 by the United States Patent and Trademark Office.		Ligand Pharmaceuticals	United States Patent and Trademark Office	7435733	October 14, 2008
‌ US Patent 9492430 Methods and compositions associated with the granulocyte colony-stimulating factor receptor	Patent 9492430 was granted and assigned to Ligand Pharmaceuticals on November, 2016 by the United States Patent and Trademark Office.	Ligand Pharmaceuticals	Ligand Pharmaceuticals	United States Patent and Trademark Office	9492430	November 15, 2016
‌ US Patent 7691895 Thrombopoietin activity modulating compounds and methods	Patent 7691895 was granted and assigned to Ligand Pharmaceuticals on April, 2010 by the United States Patent and Trademark Office.		Ligand Pharmaceuticals	United States Patent and Trademark Office	7691895	April 6, 2010
‌ US Patent 7026484 Tricyclic androgen receptor modulator compounds and methods	Patent 7026484 was granted and assigned to Ligand Pharmaceuticals on April, 2006 by the United States Patent and Trademark Office.		Ligand Pharmaceuticals	United States Patent and Trademark Office	7026484	April 11, 2006
‌ US Patent 11566041 Nucleotide prodrug compounds	Patent 11566041 was granted and assigned to Ligand Pharmaceuticals on January, 2023 by the United States Patent and Trademark Office.	Ligand Pharmaceuticals	Ligand Pharmaceuticals	United States Patent and Trademark Office	11566041	January 31, 2023
‌ US Patent 9993461 Method for treating disorders associated with glomerular function	Patent 9993461 was granted and assigned to Ligand Pharmaceuticals on June, 2018 by the United States Patent and Trademark Office.	Ligand Pharmaceuticals	Ligand Pharmaceuticals	United States Patent and Trademark Office	9993461	June 12, 2018
‌ US Patent 8193357 Androgen receptor modulator compounds	Patent 8193357 was granted and assigned to Ligand Pharmaceuticals on June, 2012 by the United States Patent and Trademark Office.		Ligand Pharmaceuticals	United States Patent and Trademark Office	8193357	June 5, 2012
‌ US Patent 7314887 Thrombopoietin activity modulating compounds and methods	Patent 7314887 was granted and assigned to Ligand Pharmaceuticals on January, 2008 by the United States Patent and Trademark Office.		Ligand Pharmaceuticals	United States Patent and Trademark Office	7314887	January 1, 2008
‌ US Patent 7727980 Tricyclic androgen receptor modulator compounds and methods	Patent 7727980 was granted and assigned to Ligand Pharmaceuticals on June, 2010 by the United States Patent and Trademark Office.		Ligand Pharmaceuticals	United States Patent and Trademark Office	7727980	June 1, 2010
‌ US Patent 10441567 Methods and compositions for modulating hormone levels	Patent 10441567 was granted and assigned to Ligand Pharmaceuticals on October, 2019 by the United States Patent and Trademark Office.	Ligand Pharmaceuticals	Ligand Pharmaceuticals	United States Patent and Trademark Office	10441567	October 15, 2019
‌ US Patent 8822467 Biaryl oxyacetic acid compounds	Patent 8822467 was granted and assigned to Ligand Pharmaceuticals on September, 2014 by the United States Patent and Trademark Office.	Ligand Pharmaceuticals	Ligand Pharmaceuticals	United States Patent and Trademark Office	8822467	September 2, 2014
‌ US Patent 9676809 Derivatives of uridine 5′-cyclophosphate useful to treat hepatitis C viral infections	Patent 9676809 was granted and assigned to Ligand Pharmaceuticals on June, 2017 by the United States Patent and Trademark Office.		Ligand Pharmaceuticals	United States Patent and Trademark Office	9676809	June 13, 2017
‌ US Patent 9662312 Method for treating glomerulosclerosis	Patent 9662312 was granted and assigned to Ligand Pharmaceuticals on May, 2017 by the United States Patent and Trademark Office.	Ligand Pharmaceuticals	Ligand Pharmaceuticals	United States Patent and Trademark Office	9662312	May 30, 2017
‌ US Patent 10150788 Prodrug compounds and uses thereof	Patent 10150788 was granted and assigned to Ligand Pharmaceuticals on December, 2018 by the United States Patent and Trademark Office.	Ligand Pharmaceuticals	Ligand Pharmaceuticals	United States Patent and Trademark Office	10150788	December 11, 2018
‌ US Patent 10106500 Selective androgen receptor modulators (SARMs) and uses thereof	Patent 10106500 was granted and assigned to Ligand Pharmaceuticals on October, 2018 by the United States Patent and Trademark Office.	Ligand Pharmaceuticals	Ligand Pharmaceuticals	United States Patent and Trademark Office	10106500	October 23, 2018
‌ US Patent 10730831 Selective androgen receptor modulators (SARMs) and uses thereof		Ligand Pharmaceuticals	Ligand Pharmaceuticals	United States Patent and Trademark Office	10730831	August 4, 2020
‌ US Patent 7442696 Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses	Patent 7442696 was granted and assigned to Ligand Pharmaceuticals on October, 2008 by the United States Patent and Trademark Office.		Ligand Pharmaceuticals	United States Patent and Trademark Office	7442696	October 28, 2008

Results per page:

47 results

0 selected

47 results

0 selected